Table 3 Prevalence of clinically significant drug interactions
Antiretroviral drug | Drug paired | Number of interactions, n | % of 44 PDDIs |
|---|---|---|---|
Risk X (avoid combination) | |||
Raltegravir | Magnesium Carbonate | 2 | 4.5% |
Raltegravir | Magnesium Oxide | 1 | 2.3% |
Risk D (consider therapy modification) | |||
Dolutegravir | Calcium Carbonate | 12 | 27.3% |
Dolutegravir | Magnesium Carbonate | 12 | 27.3% |
Dolutegravir | Magnesium Oxide | 3 | 6.8% |
Raltegravir | Calcium Carbonate | 2 | 4.5% |
Rilpivirine | Calcium Carbonate | 2 | 4.5% |
Rilpivirine | Magnesium Carbonate | 2 | 4.5% |
Cobicistat | Rosuvastatin | 1 | 2.3% |
Darunavir | Nifedipine | 1 | 2.3% |
Elvitegravir | Calcium Carbonate | 1 | 2.3% |
Elvitegravir | Calcium L-Aspartate Hydrate a | 1 | 2.3% |
Elvitegravir | Magnesium Carbonate | 1 | 2.3% |
Raltegravir | Ferric Citrate | 1 | 2.3% |
Ritonavir | Nifedipine | 1 | 2.3% |
Tenofovir alafenamide fumarate | Loxoprofen | 1 | 2.3% |